Futura Medical product development continues 'apace'

Transdermal technology-focussed healthcare company Futura Medical was set to hold its annual general meeting on Wednesday, with chairman John Clarke telling the gathered investors that the firm’s development and commercialisation of its product pipeline had continued apace.

The AIM-traded company made “good progress” in the year to date, Clarke added, especially across its sexual health products, labelled MED2002 and CSD500.

“As announced at the end of last month, we have received constructive feedback from US and UK regulatory authorities on the clinical and regulatory pathway for MED2002, our topical gel for erectile dysfunction.

“As a result of this feedback we expect our Phase III programme of MED2002 to proceed as planned, with the first patient dosed in Q4 this year.

“We continue to receive significant commercial interest in MED2002 from potential licensing partners and negotiations are ongoing.”

On CSD500, which Clarke described as the company’s “novel erectogenic condom”, Futura was currently assisting all of its EU licensing partners “wherever required” with their launch plans in a number of countries.

“In addition, we have in production two manufacturing orders from our licensing partner for the Middle East and North Africa, following its launch of CSD500 in Saudi Arabia earlier this year.”

Futura also continued in discussions on the out-licensing of its two pain relief products, TIB200 and TPR100, with potential licensing partners, Clarke said.

“Futura continues to benefit from a strong financial position and we look forward to the year ahead with confidence.”